Search

Your search keyword '"Østerlind A"' showing total 569 results
Start Over Author "Østerlind A"
569 results on '"Østerlind A"'

1. Initial treatment and survival in 4163 Danish patients with pancreatic cancer: A nationwide unselected real-world register study

Author

Rasmussen, Louise S., Fristrup, Claus W., Jensen, Benny V., Pfeiffer, Per, Weber, Britta, Yilmaz, Mette K., Poulsen, Laurids Ø., Ladekarl, Morten, Østerlind, Kell, Larsen, Jim S., Skuladottir, Hella, Hansen, Carsten P., Mortensen, Michael B., Mortensen, Frank V., Sall, Mogens, Detlefsen, Sönke, Bøgsted, Martin, and Falkmer, Ursula G.

Published
2020
Full Text
View/download PDF

5. Live tissue versus simulation training for emergency procedures: Is simulation ready to replace live tissue?

Author

Bailey, Jeff, Dorlac, Warren, Shotto, Rob, Norfleet, Jack, Coakley, Tim, Bowyer, Mark, Murray, Bousseau, Shapiro, Mark, Manson, Roberto, Moloff, Al, Burgess, Deborah, Hester, Robert, Lewandowski, William, Armstrong, Waymon, McNeff, Jack, Cannon-Bowers, Jan, Hardeman, Joanne, Guido, Jenny, Giering, Cole, Rohrlack, Robert, Acosta, Jessica, Patel, Raj, Green, Zachary, Roan, Ronald, Robinett, Adam, Snyder, Scott, Soni, Bharat, Davis, Dale, Rodriquez, Lina, Shum, Phillip, Osterlind, Steve, Cooper, Chris, Uhlich, Rindi, Stephan, Christina, Tucker, John, Anton, John, Shuford, Ray, Strayhorn, Catherine, Anton, Emily, Baez, Nadine, Honold, Erin, Barnes, Stephen L., Bukoski, Alex, Kerby, Jeffrey D., Llerena, Luis, and Armstrong, John H.

Published
2016
Full Text
View/download PDF

7. Therapy with pembrolizumab in treatment-naïve patients with nonmetastatic, mismatch repair deficient colorectal cancer

Author

Eefsen, Rikke Løvendahl, Larsen, Jim S., Klarskov, Louise L., Altaf, Rahim, Høgdall, Estrid, Ingeholm, Peter, Lykke, Jakob, Nielsen, Dorte L., Pfeiffer, Per, Poulsen, Laurids, Qvortrup, Camilla, Schou, Jakob V., Mau-Sørensen, Morten, Østerlind, Kell, Jensen, Benny V., Eefsen, Rikke Løvendahl, Larsen, Jim S., Klarskov, Louise L., Altaf, Rahim, Høgdall, Estrid, Ingeholm, Peter, Lykke, Jakob, Nielsen, Dorte L., Pfeiffer, Per, Poulsen, Laurids, Qvortrup, Camilla, Schou, Jakob V., Mau-Sørensen, Morten, Østerlind, Kell, and Jensen, Benny V.

Abstract

Therapy with immune checkpoint inhibitors (ICI) is effective in patients with metastatic mismatch-repair deficient (dMMR) colorectal cancer (CRC); however, data on treatment with neoadjuvant ICI in patients with locally advanced CRC are limited. From March 2019 to June 2020, five Danish oncological centers treated 10 patients with a treatment-naïve dMMR CRC with preoperative pembrolizumab, 9 with a nonmetastatic, unresectable colon cancer and 1 with a locally advanced rectum cancer. All 10 patients were evaluated regularly at a multidisciplinary team (MDT) meeting, and they all had a radical resection after a median of 8 cycles (range 2-13) of pembrolizumab. A microscopic evaluation of the resected tumors revealed no remaining tumor cells in five patients, while five still had tumor cells present. The patients were given no additional therapy. No recurrences were reported after a median follow-up of 26 months (range 23-38.5 months). Biopsies from Danish patients with CRC are routinely screened for dMMR proteins. In 2017, data from the Danish Colorectal Cancer Group showed that 19% (565/3000) of the patients with colon cancer and 1.5% (19/1279) of those with rectum cancer had an dMMR tumor. Among the patients with MMR determination, 26% (99/384) patients had a T4 dMMR colon cancer; thus, the 10 patients treated with neoadjuvant pembrolizumab comprised about 9% of the patients with a T4 dMMR colon cancer (9/99) and 5% of patients with dMMR rectal cancer (1/19). Therapy with pembrolizumab was feasible and effective. Larger prospective trials are needed to confirm our findings., Therapy with immune checkpoint inhibitors (ICI) is effective in patients with metastatic mismatch-repair deficient (dMMR) colorectal cancer (CRC); however, data on treatment with neoadjuvant ICI in patients with locally advanced CRC are limited. From March 2019 to June 2020, five Danish oncological centers treated 10 patients with a treatment-naïve dMMR CRC with preoperative pembrolizumab, 9 with a nonmetastatic, unresectable colon cancer and 1 with a locally advanced rectum cancer. All 10 patients were evaluated regularly at a multidisciplinary team (MDT) meeting, and they all had a radical resection after a median of 8 cycles (range 2-13) of pembrolizumab. A microscopic evaluation of the resected tumors revealed no remaining tumor cells in five patients, while five still had tumor cells present. The patients were given no additional therapy. No recurrences were reported after a median follow-up of 26 months (range 23-38.5 months). Biopsies from Danish patients with CRC are routinely screened for dMMR proteins. In 2017, data from the Danish Colorectal Cancer Group showed that 19% (565/3000) of the patients with colon cancer and 1.5% (19/1279) of those with rectum cancer had an dMMR tumor. Among the patients with MMR determination, 26% (99/384) patients had a T4 dMMR colon cancer; thus, the 10 patients treated with neoadjuvant pembrolizumab comprised about 9% of the patients with a T4 dMMR colon cancer (9/99) and 5% of patients with dMMR rectal cancer (1/19). Therapy with pembrolizumab was feasible and effective. Larger prospective trials are needed to confirm our findings.

Published
2023

8. Supplementary Methods, Tables 1-5, Figures 1-4 from Development and Validation of a Melanoma Risk Score Based on Pooled Data from 16 Case–Control Studies

Author

Davies, John R., primary, Chang, Yu-mei, primary, Bishop, D. Timothy, primary, Armstrong, Bruce K., primary, Bataille, Veronique, primary, Bergman, Wilma, primary, Berwick, Marianne, primary, Bracci, Paige M., primary, Elwood, J. Mark, primary, Ernstoff, Marc S., primary, Green, Adele, primary, Gruis, Nelleke A., primary, Holly, Elizabeth A., primary, Ingvar, Christian, primary, Kanetsky, Peter A., primary, Karagas, Margaret R., primary, Lee, Tim K., primary, Le Marchand, Loïc, primary, Mackie, Rona M., primary, Olsson, Håkan, primary, Østerlind, Anne, primary, Rebbeck, Timothy R., primary, Reich, Kristian, primary, Sasieni, Peter, primary, Siskind, Victor, primary, Swerdlow, Anthony J., primary, Titus, Linda, primary, Zens, Michael S., primary, Ziegler, Andreas, primary, Gallagher, Richard P., primary, Barrett, Jennifer H., primary, and Newton-Bishop, Julia, primary

Published
2023
Full Text
View/download PDF

9. Data from Development and Validation of a Melanoma Risk Score Based on Pooled Data from 16 Case–Control Studies

Author

Davies, John R., primary, Chang, Yu-mei, primary, Bishop, D. Timothy, primary, Armstrong, Bruce K., primary, Bataille, Veronique, primary, Bergman, Wilma, primary, Berwick, Marianne, primary, Bracci, Paige M., primary, Elwood, J. Mark, primary, Ernstoff, Marc S., primary, Green, Adele, primary, Gruis, Nelleke A., primary, Holly, Elizabeth A., primary, Ingvar, Christian, primary, Kanetsky, Peter A., primary, Karagas, Margaret R., primary, Lee, Tim K., primary, Le Marchand, Loïc, primary, Mackie, Rona M., primary, Olsson, Håkan, primary, Østerlind, Anne, primary, Rebbeck, Timothy R., primary, Reich, Kristian, primary, Sasieni, Peter, primary, Siskind, Victor, primary, Swerdlow, Anthony J., primary, Titus, Linda, primary, Zens, Michael S., primary, Ziegler, Andreas, primary, Gallagher, Richard P., primary, Barrett, Jennifer H., primary, and Newton-Bishop, Julia, primary

Published
2023
Full Text
View/download PDF

10. Supplementary Methods, Tables 1-5, Figures 1-4 from Development and Validation of a Melanoma Risk Score Based on Pooled Data from 16 Case–Control Studies

Author

Julia Newton-Bishop, Jennifer H. Barrett, Richard P. Gallagher, Andreas Ziegler, Michael S. Zens, Linda Titus, Anthony J. Swerdlow, Victor Siskind, Peter Sasieni, Kristian Reich, Timothy R. Rebbeck, Anne Østerlind, Håkan Olsson, Rona M. Mackie, Loïc Le Marchand, Tim K. Lee, Margaret R. Karagas, Peter A. Kanetsky, Christian Ingvar, Elizabeth A. Holly, Nelleke A. Gruis, Adele Green, Marc S. Ernstoff, J. Mark Elwood, Paige M. Bracci, Marianne Berwick, Wilma Bergman, Veronique Bataille, Bruce K. Armstrong, D. Timothy Bishop, Yu-mei Chang, and John R. Davies

Abstract

Supplementary Methods, Tables 1-5, Figures 1-4. Contains additional Methods and Materials on the coding of variables in the risk model, recruitment of cases to the Leeds Case-Control study, imputation, comparing self reported and nurse derived mole counts and calculations for estimating absolute risk. Contains Tables 1-5 on missingness of pooled data, risk assessment for the Leeds dataset including imputed cases, comparisons of self classification and nurse classification of mole count/freckling in the Leeds controls. Contains Figures 1-4 showing the distribution of risk scores in the pooled and Leeds data, a bland-altman plot comparing nurse and self assessment of mole count on the back in Leeds controls and a cartoon used in the Leeds Case-Control study to determine mole count.

Published
2023
Full Text
View/download PDF

12. Therapy with pembrolizumab in treatment‐naïve patients with nonmetastatic, mismatch repair deficient colorectal cancer

Author

Eefsen, Rikke Løvendahl, primary, Larsen, Jim S., additional, Klarskov, Louise L., additional, Altaf, Rahim, additional, Høgdall, Estrid, additional, Ingeholm, Peter, additional, Lykke, Jakob, additional, Nielsen, Dorte L., additional, Pfeiffer, Per, additional, Poulsen, Laurids Ø., additional, Qvortrup, Camilla, additional, Schou, Jakob V., additional, Mau‐Sørensen, Morten, additional, Østerlind, Kell, additional, and Jensen, Benny V., additional

Published
2023
Full Text
View/download PDF

13. Therapy with pembrolizumab in treatment-naïve patients with non-metastatic, mismatch repair deficient colorectal cancer

Author

Rikke Løvendahl Eefsen, Jim S. Larsen, Louise L. Klarskov, Rahim Altaf, Estrid Høgdall, Peter Ingeholm, Jakob Lykke, Dorte L. Nielsen, Per Pfeiffer, Laurids Ø. Poulsen, Camilla Qvortrup, Jakob V. Schou, Morten Mau‐Sørensen, Kell Østerlind, and Benny V. Jensen

Subjects
Cancer Research, Oncology, checkpoint inhibition, mismatch repair deficient, colorectal cancer, pembrolizumab, unresectable
Abstract

Therapy with immune checkpoint inhibitors (ICI) is effective in patients with metastatic mismatch-repair deficient (dMMR) colorectal cancer (CRC); however, data on treatment with neoadjuvant ICI in patients with locally advanced CRC are limited. From March 2019 to June 2020, five Danish oncological centers treated 10 patients with a treatment-naïve dMMR CRC with pre-operative pembrolizumab, 9 with a non-metastatic, unresectable colon cancer and 1 with a locally advanced rectum cancer. All 10 patients were evaluated regularly at a multidisciplinary team (MDT) meeting, and they all had a radical resection after a median of 8 cycles (range 2-13) of pembrolizumab. A microscopic evaluation of the resected tumors revealed no remaining tumor cells in 5 patients, while 5 still had tumor cells present. The patients were given no additional therapy. No recurrences were reported after a median follow-up of 26 months (range 23-38.5 months). Biopsies from Danish patients with CRC are routinely screened for dMMR proteins. In 2017, data from the Danish Colorectal Cancer Group showed that 19% (565/3000) of the patients with colon cancer and 1.5% (19/1279) of those with rectum cancer had an dMMR tumor. Among the patients with MMR determination, 26% (99/384) patients had a T4 dMMR colon cancer; thus, the 10 patients treated with neoadjuvant pembrolizumab comprised about 9% of the patients with a T4 dMMR colon cancer (9/99) and 5% of patients with dMMR rectal cancer (1/19). Therapy with pembrolizumab was feasible and effective. Larger prospective trials are needed to confirm our findings. This article is protected by copyright. All rights reserved.

Published
2022
Full Text
View/download PDF

16. Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings

Author

Andel, J., Balcke, P., Benedicic, B., Eisterer, W., Fridrik, M., Jagdt, B., Keil, F., Kretschmer, A., Krippl, P., Oexle, H., Pecherstorfer, M., Samonigg, H., Schmid, M., Thaler, J., Tinchon, C., Weiss, H., Arts, J., De Man, M., Demolin, G., Janssens, J., Polus, M., Benczikova, B., Melichar, B., Prausova, J., Vitek, P., Andersen, F.Z., Jensen, B.B., Keldsen, N., Østerlind, K., Vistisen, K., Elme, A., Magi, A., Ojamaa, K., Ristamäki, R., Salminen, T., Ben Abdelghani, M., Bouche, O., Borg, C., Bouhier-Leporrier, K., Breysacher, G., Chone, L., Clavero Fabri, M.-C., Deplanque, G., Desseigne, F., Dourthe, L.-M., Ezenfis, J., Faroux, R., François, E., Garnier, C., Gaspard, M.-H., Hebbar, M., Illory, J.F., Kaminsky, M.-C., Lecomte, T., Legoux, J.-L., Levache, B., Lobry, C., Lotz, J.-P., Mabro, M., Manet-Lacombe, S., Manfredi, S., Matysiak Budnik, T., Miglianico, L., Mineur, L., Moullet, I., Naman, H., Nouyrigat, P., Oziel-Taieb, S., Perrier, H., Pezet, D., Philip, J., Pottier, V., Porneuf, M., Ramdani, M., Re, D., Rinaldi, Y., Spaeth, D., Taieb, J., Terrebonne, E., Texereau, P., Thirot Bidault, A., Tournigand, C., Tubiana-Mathieu, N., Vantelon, J.-M., Viret, F., Ychou, M., Bangerter, M., Bertram, M.E., Bohnsteen, B., Brinkmann, L., Caca, K., Constantin, C., Cordes, H.-J., Dietrich, G., Eggert, J., Engel, E., Fahlke, J., Fensterer, H., Florschütz, A., Folprecht, G., Forstbauer, H., Freier, W., Freund, M., Frickhofen, N., Gäbele, E., Geißler, M., Gieseler, F., Göhler, T., Graeven, U., Groschek, M., Grundeis, M., Hacker, U., Hagen, V., Hebart, H.F., Hegewisch-Becker, S., Heike, M., Herrmann, T., Hildebrandt, B., Höffkes, H.-G., Hübner, G., Hübner, J., Kettner, E., Kneba, M., Kohnke, J.W., Kojouharoff, G., König, C., Kretzschmar, A., Kröning, H., Kürner, K., Lammert, F., Lerchenmüller, C., Lück, A., Meiler, J., Mergenthaler, H.-G., Müller, L., Müller-Naendrup, C., Nusch, A., Papke, J., Porschen, R., Rädle, J., Reddemann, C., Ridwelski, K., Riera-Knorrenschild, J., Rudi, J., Schmalenberger, A., Schimanski, C.-C., Schlegel, F., Schlichting, C., Schmidt, P., Schmiegel, W., Schmitz, S., Schulze-Bergkamen, H., Schwaner, I., Schwarzer, A., Schwerdtfeger, M., Selbach, J., Sieber, M., Siebler, J., Staib, P., Stauch, M., Steffens, C.-C., Stübs, P., Tischendorf, J., Trarbach, T., Tummes, D., Valdix, A.-R., Vogel, A., Von Wichert, G.P.L., Walther, M., Welslau, W., Wilhelm, G., Wobster, H., Wolf, T., Zeigenhagen, N., Zomorodbaksch, B., Batman, E., Bloemendal, H.J., Kehrer, D.F.S., Guren, T., Indrebø, G., Kersten, C., Soerbye, H., Fragoso, M., Fragoso, R., Mellidez, J.C., Sa, A., Aljobran, A., Darwish, T., Alonso-Orduna, V., Aparicio, J., Aranda, E., Bosch, C., Galan-Brotons, A., Busquier Hernandez, I., Camara, J.C., Campos Cervera, J.M., Carlos Garcia Giron, C., Del Prado, P.M., Donnay, O., Escudero, P., Falco, E., Gallego Plazas, J., Garcia Alfonso, P., Gonzalez Flores, E., Gravalos, C., Guardeno, R., Juárez, A., Lopez Ladron, A., Losa Gaspa, F., MªVicent Vergé, J., Marcuello Gaspar, E., Massuti Sureda, B., Molina, J., Montero, I.C., Muñoa, A.L., Naranjo, M.B., Oruezabal Moreno, M.J., Pachón Olmos, V., Pericay, C., Reina Zoilo, J.J., Rivera, F., Ruiz Casado, A., Safont, M.J., Salud Salvia, A., Tobena, M., Toral, J.C., Valenti, V., Valladares Ayerbes, M., Vieitez, J.M., Vera, R., Berglund, A., Fernebro, E., Hess-Umbricht, V., Pless, M., Popescu, R., Winterhalder, R., Kubicka, S., Greil, R., André, T., Bennouna, J., Sastre, J., Van Cutsem, E., von Moos, R., Österlund, P., Reyes-Rivera, I., Müller, T., Makrutzki, M., and Arnold, D.

Published
2013
Full Text
View/download PDF

18. Patterns of Palliative Chemotherapy and Survival in Patients With Pancreatic Cancer Focusing on Age

Author

Mette Karen Yilmaz, Ursula Falkmer, Kell Østerlind, Louise Skau Rasmussen, Britta Weber, Halla Skuladottir, Laurids Østergaard Poulsen, Martin Bøgsted, Benny V. Jensen, Jim S. Larsen, Per Pfeiffer, Claus Wilki Fristrup, and Morten Ladekarl

Subjects
Male, Time Factors, Databases, Factual, Denmark, Endocrinology, Diabetes and Metabolism, Registry study, pancreatic cancer, Deoxycytidine, 0302 clinical medicine, Endocrinology, Antineoplastic Combined Chemotherapy Protocols, Registries, Practice Patterns, Physicians', Aged, 80 and over, registry study, Palliative Care, Hazard ratio, Age Factors, Middle Aged, Treatment Outcome, 030220 oncology & carcinogenesis, language, Female, 030211 gastroenterology & hepatology, medicine.drug, Adult, Antimetabolites, Antineoplastic, medicine.medical_specialty, Clinical Decision-Making, survival, Danish, 03 medical and health sciences, Internal medicine, Pancreatic cancer, Internal Medicine, medicine, Overall survival, Humans, palliative chemotherapy pattern, In patient, Aged, Hepatology, business.industry, Palliative chemotherapy, medicine.disease, Gemcitabine, Drug Utilization, language.human_language, Pancreatic Neoplasms, age, second-line treatment, business
Abstract

OBJECTIVES: The aim of this study was to identify patterns of palliative chemotherapy (CTh) and the associated overall survival (OS) in patients with pancreatic cancer, with specific focus on age.METHODS: Between May 1, 2011, and April 30, 2016, 4260 patients were registered in the Danish Pancreatic Cancer Database. The 1715 patients receiving palliative CTh were retrieved. Age was grouped into less than 70, 70 to less than 75, and 75 years or more.RESULTS: Of the 1715 patients receiving first-line CTh, 586 (34%) underwent second-line CTh and 151 (9%) third-line CTh. First-line gemcitabine resulted in a significant worse survival compared with combination CTh, hazard ratio 1.51. For combination CTh, OS differed between the age groups, P < 0.01. The median OS in the less than 70 years (n = 547), 70 to less than 75 years (n = 163), and 75 years or more (n = 67) groups were 9.3, 9.6, and 7.2 months, respectively. No differences in survival were observed among patients receiving first-line gemcitabine (P = 0.35).CONCLUSIONS: Our findings are useful in treatment-related decision making in patients with pancreatic cancer. A significant survival benefit was observed for all patients after first-line combination CTh. The effect of combination CTh was most prominent among patients aged less than 75 years. By age, no differences in survival were observed in those receiving gemcitabine.

Published
2021
Full Text
View/download PDF

21. Interindividual changes in peak oxygen consumption in patients with colorectal cancer following endurance training: a secondary analysis of the I-WALK-CRC study

Author

Jesper Christensen, Peter-Martin Krarup, Sarah Thorsen-Streit, Simon Nørskov Thomsen, Kell Østerlind, Bente Klarlund Pedersen, Kirsten Vistisen, Jens Osterkamp, and Anna Sundberg

Subjects
Male, Oncology, medicine.medical_specialty, Adjuvant chemotherapy, Colorectal cancer, Denmark, Walking, Risk profile, Oxygen Consumption, Sex Factors, Endurance training, Secondary analysis, Internal medicine, medicine, Humans, Radiology, Nuclear Medicine and imaging, In patient, Stage (cooking), Rectal Neoplasms, business.industry, Age Factors, Treatment options, Hematology, General Medicine, Middle Aged, medicine.disease, Walking Speed, Endurance Training, Colonic Neoplasms, Female, business
Abstract

Surgical resection with adjuvant chemotherapy according to stage and risk profile is the main treatment option for non-metastatic colorectal cancer (CRC). However, pervasive side effects, including...

Published
2020
Full Text
View/download PDF

25. Disparity in use of modern combination chemotherapy associated with facility type influences survival of 2655 patients with advanced pancreatic cancer

Author

Morten Ladekarl, Louise Skau Rasmussen, Jakob Kirkegård, Inna Chen, Per Pfeiffer, Britta Weber, Halla Skuladottir, Kell Østerlind, Jim Stenfatt Larsen, Frank Viborg Mortensen, Henriette Engberg, Henrik Møller, and Claus Wilki Fristrup

Subjects
Hematology, General Medicine, Pancreatic Neoplasms, Oncology, disparity, pancreas cancer, Pancreatic Neoplasms/drug therapy, hospital facility, Humans, Chemotherapy, Drug Therapy, Combination, Radiology, Nuclear Medicine and imaging, prognosis, Hospitals, High-Volume, Proportional Hazards Models, Retrospective Studies
Abstract

AIM: Academic and high volume hospitals have better outcome for pancreatic cancer (PC) surgery, but there are no reports on oncological treatment. We aimed to determine the influence of facility types on overall survival (OS) after treatment with chemotherapy for inoperable PC.MATERIAL AND METHODS: 2,657 patients were treated in Denmark from 2012 to 2018 and registered in the Danish Pancreatic Cancer Database. Facilities were classified as either secondary oncological units or comprehensive, tertiary referral cancer centers.RESULTS: The average yearly number of patients seen at the four tertiary facilities was 71, and 31 at the four secondary facilities. Patients at secondary facilities were older, more frequently had severe comorbidity and lived in non-urban municipalities. As compared to combination chemotherapy, monotherapy with gemcitabine was used more often (59%) in secondary facilities than in tertiary (34%). The unadjusted median OS was 7.7 months at tertiary and 6.1 months at secondary facilities. The adjusted hazard ratio (HR) of 1.16 (confidence interval 1.07-1.27) demonstrated an excess risk of death for patients treated at secondary facilities, which disappeared when taking type of chemotherapy used into account. Hence, more use of combination chemotherapy was associated with the observed improved OS of patients treated at tertiary facilities. Declining HR's per year of first treatment indicated improved outcomes with time, however the difference among facility types remained significant.DISCUSSION: Equal access to modern combination chemotherapy at all facilities on a national level is essential to ensure equality in treatment results.

Published
2022
Full Text
View/download PDF

29. Disparity in use of modern combination chemotherapy associated with facility type influences survival of 2655 patients with advanced pancreatic cancer

Author

Ladekarl, Morten, primary, Rasmussen, Louise Skau, additional, Kirkegård, Jakob, additional, Chen, Inna, additional, Pfeiffer, Per, additional, Weber, Britta, additional, Skuladottir, Halla, additional, Østerlind, Kell, additional, Larsen, Jim Stenfatt, additional, Mortensen, Frank Viborg, additional, Engberg, Henriette, additional, Møller, Henrik, additional, and Fristrup, Claus Wilki, additional

Published
2021
Full Text
View/download PDF

36. Patterns of Palliative Chemotherapy and Survival in Patients With Pancreatic Cancer Focusing on Age

Author

Rasmussen, Louise S., primary, Fristrup, Claus W., additional, Jensen, Benny V., additional, Pfeiffer, Per, additional, Weber, Britta, additional, Yilmaz, Mette K., additional, Poulsen, Laurids Ø., additional, Ladekarl, Morten, additional, Østerlind, Kell, additional, Larsen, Jim S., additional, Skuladottir, Halla, additional, Bøgsted, Martin, additional, and Falkmer, Ursula G., additional

Published
2021
Full Text
View/download PDF

37. Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings†

Author

Kubicka, S., Greil, R., André, T., Bennouna, J., Sastre, J., Van Cutsem, E., von Moos, R., Österlund, P., Reyes-Rivera, I., Müller, T., Makrutzki, M., Arnold, D., Andel, J, Balcke, P, Benedicic, B, Eisterer, W, Fridrik, M, Jagdt, B, Keil, F, Kretschmer, A, Krippl, P, Oexle, H, Pecherstorfer, M, Samonigg, H, Schmid, M, Thaler, J, Tinchon, C, Weiss, H., Arts, J, De Man, M, Demolin, G, Janssens, J, Polus, M., Benczikova, B, Melichar, B, Prausova, J, Vitek, P., Andersen, FZ, Jensen, BB, Keldsen, N, Østerlind, K, Vistisen, K., Elme, A, Magi, A, Ojamaa, K., Ristamäki, R, Salminen, T., Ben Abdelghani, M, Bouche, O, Borg, C, Bouhier-Leporrier, K, Breysacher, G, Chone, L, Clavero Fabri, M-C, Deplanque, G, Desseigne, F, Dourthe, L-M, Ezenfis, J, Faroux, R, François, E, Garnier, C, Gaspard, M-H, Hebbar, M, Illory, JF, Kaminsky, M-C, Lecomte, T, Legoux, J-L, Levache, B, Lobry, C, Lotz, J-P, Mabro, M, Manet-Lacombe, S, Manfredi, S, Matysiak Budnik, T, Miglianico, L, Mineur, L, Moullet, I, Naman, H, Nouyrigat, P, Oziel-Taieb, S, Perrier, H, Pezet, D, Philip, J, Pottier, V, Porneuf, M, Ramdani, M, Re, D, Rinaldi, Y, Spaeth, D, Taieb, J, Terrebonne, E, Texereau, P, Thirot Bidault, A, Tournigand, C, Tubiana-Mathieu, N, Vantelon, J-M, Viret, F, Ychou, M., Bangerter, M, Bertram, ME, Bohnsteen, B, Brinkmann, L, Caca, K, Constantin, C, Cordes, H-J, Dietrich, G, Eggert, J, Engel, E, Fahlke, J, Fensterer, H, Florschütz, A, Folprecht, G, Forstbauer, H, Freier, W, Freund, M, Frickhofen, N, Gäbele, E, Geiler, M, Gieseler, F, Göhler, T, Graeven, U, Groschek, M, Grundeis, M, Hacker, U, Hagen, V, Hebart, HF, Hegewisch-Becker, S, Heike, M, Herrmann, T, Hildebrandt, B, Höffkes, H-G, Hübner, G, Hübner, J, Kettner, E, Kneba, M, Kohnke, JW, Kojouharoff, G, König, C, Kretzschmar, A, Kröning, H, Kürner, K, Lammert, F, Lerchenmüller, C, Lück, A, Meiler, J, Mergenthaler, H-G, Müller, L, Müller-Naendrup, C, Nusch, A, Papke, J, Porschen, R, Rädle, J, Reddemann, C, Ridwelski, K, Riera-Knorrenschild, J, Rudi, J, Schmalenberger, A, Schimanski, C-C, Schlegel, F, Schlichting, C, Schmidt, P, Schmiegel, W, Schmitz, S, Schulze-Bergkamen, H, Schwaner, I, Schwarzer, A, Schwerdtfeger, M, Selbach, J, Sieber, M, Siebler, J, Staib, P, Stauch, M, Steffens, C-C, Stübs, P, Tischendorf, J, Trarbach, T, Tummes, D, Valdix, A-R, Vogel, A, Von Wichert, GPL, Walther, M, Welslau, W, Wilhelm, G, Wobster, H, Wolf, T, Zeigenhagen, N, Zomorodbaksch, B., Batman, E, Bloemendal, HJ, Kehrer, DFS., Guren, T, Indrebø, G, Kersten, C, Soerbye, H., Fragoso, M, Fragoso, R, Mellidez, JC, Sa, A., Aljobran, A, Darwish, T., Alonso-Orduna, V, Aparicio, J, Aranda, E, Bosch, C, Galan-Brotons, A, Busquier Hernandez, I, Camara, JC, Campos Cervera, JM, Carlos Garcia Giron, C, Del Prado, PM, Donnay, O, Escudero, P, Falco, E, Gallego Plazas, J, Garcia Alfonso, P, Gonzalez Flores, E, Gravalos, C, Guardeno, R, Juárez, A, Lopez Ladron, A, Losa Gaspa, F, MVicent Vergé, J, Marcuello Gaspar, E, Massuti Sureda, B, Molina, J, Montero, IC, Muñoa, AL, Naranjo, MB, Oruezabal Moreno, MJ, Pachón Olmos, V, Pericay, C, Reina Zoilo, JJ, Rivera, F, Ruiz Casado, A, Safont, MJ, Salud Salvia, A, Tobena, M, Toral, JC, Valenti, V, Valladares Ayerbes, M, Vieitez, JM, Vera, R, Vieitez, JM., Berglund, A, Fernebro, E., Hess-Umbricht, V, Pless, M, Popescu, R, and Winterhalder, R.

Published
2013
Full Text
View/download PDF

39. Interindividual changes in peak oxygen consumption in patients with colorectal cancer following endurance training: a secondary analysis of the I-WALK-CRC study

Author

Thomsen, Simon Nørskov, primary, Sundberg, Anna, additional, Osterkamp, Jens, additional, Thorsen-Streit, Sarah, additional, Østerlind, Kell, additional, Krarup, Peter-Martin, additional, Vistisen, Kirsten, additional, Pedersen, Bente Klarlund, additional, and Christensen, Jesper Frank, additional

Published
2020
Full Text
View/download PDF

40. FLT-PET for early response evaluation of colorectal cancer patients with liver metastases: a prospective study

Author

Annika Loft, Kell Østerlind, Thomas Axelsen, Marie Benzon Mogensen, Marianne C. Aznar, Andreas Kjaer, and Ben Vainer

Subjects
lcsh:Medical physics. Medical radiology. Nuclear medicine, medicine.medical_specialty, Colorectal cancer, medicine.medical_treatment, lcsh:R895-920, Molecular imaging, Early evaluation, 030218 nuclear medicine & medical imaging, Metastasis, Lesion, 03 medical and health sciences, 0302 clinical medicine, [18 F]-3'-Deoxy-3'-fluorothymidine, Medicine, Radiology, Nuclear Medicine and imaging, Prospective cohort study, Original Research, Chemotherapy, Manchester Cancer Research Centre, medicine.diagnostic_test, business.industry, ResearchInstitutes_Networks_Beacons/mcrc, Cancer, medicine.disease, [18 F]-3′-Deoxy-3′-fluorothymidine, Positron emission tomography, 030220 oncology & carcinogenesis, Radiology, sense organs, medicine.symptom, business, FLT-PET, Progressive disease
Abstract

BACKGROUND: Fluoro-L-thymidine (FLT) is a positron emission tomography/computed tomography (PET/CT) tracer which reflects proliferative activity in a cancer lesion. The main objective of this prospective explorative study was to evaluate whether FLT-PET can be used for the early evaluation of treatment response in colorectal cancer patients (CRC) with liver metastases. Patients with metastatic CRC having at least one measurable (>1 cm) liver metastasis receiving first-line chemotherapy were included. A FLT-PET/CT scan was performed at baseline and after the first treatment. The maximum and mean standardised uptake values (SUVmax, SUVmean) were measured. After three cycles of chemotherapy, treatment response was assessed by CT scan based on RECIST 1.1.RESULTS: Thirty-nine consecutive patients were included of which 27 were evaluable. Dropout was mainly due to disease complications. Nineteen patients (70%) had a partial response, seven (26%) had stable disease and one (4%) had progressive disease. A total of 23 patients (85%) had a decrease in FLT uptake following the first treatment. The patient with progressive disease had the highest increase in FLT uptake in SUVmax. There was no correlation between the response according to RECIST and the early changes in FLT uptake measured as SUVmax(p = 0.24).CONCLUSIONS: No correlation was found between early changes in FLT uptake after the first cycle of treatment and the response evaluated from subsequent CT scans. It seems unlikely that FLT-PET can be used on its own for the early response evaluation of metastatic CRC.

Published
2017
Full Text
View/download PDF

41. Sun exposure and melanoma risk at different latitudes: a pooled analysis of 5700 cases and 7216 controls

Author

Chang, Yu-mei, Barrett, Jennifer H, Bishop, D Timothy, Armstrong, Bruce K, Bataille, Veronique, Bergman, Wilma, Berwick, Marianne, Bracci, Paige M, Elwood, J Mark, Ernstoff, Marc S, Gallagher, Richard P, Green, Adèle C, Gruis, Nelleke A, Holly, Elizabeth A, Ingvar, Christian, Kanetsky, Peter A, Karagas, Margaret R, Lee, Tim K, Le Marchand, Loïc, Mackie, Rona M, Olsson, Håkan, Østerlind, Anne, Rebbeck, Timothy R, Sasieni, Peter, Siskind, Victor, Swerdlow, Anthony J, Titus-Ernstoff, Linda, Zens, Michael S, and Newton-Bishop, Julia A

Published
2009

42. Disparity in use of modern combination chemotherapy associated with facility type influences survival of 2655 patients with advanced pancreatic cancer.

Author

Ladekarl, Morten, Rasmussen, Louise Skau, Kirkegård, Jakob, Chen, Inna, Pfeiffer, Per, Weber, Britta, Skuladottir, Halla, Østerlind, Kell, Larsen, Jim Stenfatt, Mortensen, Frank Viborg, Engberg, Henriette, Møller, Henrik, and Fristrup, Claus Wilki

Subjects
MORTALITY risk factors, THERAPEUTIC use of antineoplastic agents, PANCREATIC tumors, HEALTH facilities, CONFIDENCE intervals, CANCER chemotherapy, AGE distribution, TERTIARY care, ANTIMETABOLITES, COMORBIDITY, PHARMACODYNAMICS
Abstract

Academic and high volume hospitals have better outcome for pancreatic cancer (PC) surgery, but there are no reports on oncological treatment. We aimed to determine the influence of facility types on overall survival (OS) after treatment with chemotherapy for inoperable PC. 2,657 patients were treated in Denmark from 2012 to 2018 and registered in the Danish Pancreatic Cancer Database. Facilities were classified as either secondary oncological units or comprehensive, tertiary referral cancer centers. The average yearly number of patients seen at the four tertiary facilities was 71, and 31 at the four secondary facilities. Patients at secondary facilities were older, more frequently had severe comorbidity and lived in non-urban municipalities. As compared to combination chemotherapy, monotherapy with gemcitabine was used more often (59%) in secondary facilities than in tertiary (34%). The unadjusted median OS was 7.7 months at tertiary and 6.1 months at secondary facilities. The adjusted hazard ratio (HR) of 1.16 (confidence interval 1.07–1.27) demonstrated an excess risk of death for patients treated at secondary facilities, which disappeared when taking type of chemotherapy used into account. Hence, more use of combination chemotherapy was associated with the observed improved OS of patients treated at tertiary facilities. Declining HR's per year of first treatment indicated improved outcomes with time, however the difference among facility types remained significant. Equal access to modern combination chemotherapy at all facilities on a national level is essential to ensure equality in treatment results. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

43. The effect of postoperative gemcitabine on overall survival in patients with resected pancreatic cancer: A nationwide population-based Danish register study

Author

Sönke Detlefsen, Laurids Østergaard Poulsen, Per Pfeiffer, Martin Bøgsted, Claus Wilki Fristrup, Mogens Sall, Carsten Palnæs Hansen, Morten Ladekarl, Louise Skau Rasmussen, Mette Karen Yilmaz, Kell Østerlind, Frank Viborg Mortensen, Michael Bau Mortensen, and Benny Vittrup

Subjects
Oncology, Male, Pancreatic Neoplasms/pathology, Denmark, Deoxycytidine, 030218 nuclear medicine & medical imaging, law.invention, 0302 clinical medicine, Deoxycytidine/analogs & derivatives, Postoperative Complications, Randomized controlled trial, law, Prospective Studies, Prospective cohort study, Adenocarcinoma/pathology, Standard treatment, Hematology, General Medicine, Middle Aged, Antimetabolites, Antineoplastic/therapeutic use, Prognosis, Survival Rate, 030220 oncology & carcinogenesis, language, Adenocarcinoma, Female, medicine.drug, Adult, medicine.medical_specialty, Antimetabolites, Antineoplastic, Danish, 03 medical and health sciences, Pancreatectomy, Internal medicine, Pancreatic cancer, Pancreatectomy/adverse effects, medicine, Humans, Radiology, Nuclear Medicine and imaging, Survival rate, Aged, business.industry, medicine.disease, Gemcitabine, language.human_language, Denmark/epidemiology, Pancreatic Neoplasms, Postoperative Complications/drug therapy, business, Follow-Up Studies
Abstract

Background: Adjuvant chemotherapy following curative resection is the standard treatment for pancreatic adenocarcinoma (PC). Randomized clinical trials using gemcitabine have shown a median overall survival (mOS) of 2 years and a 5-year survival rate of 15-20%. However, the effect of gemcitabine outside these trials is less clear. We examined the effect of postoperative gemcitabine on survival in an unselected cohort of patients receiving curative resection for PC in Denmark during a five-year period. Material and methods: From 1 May 2011 to 30 April 2016, 731 patients treated with curative resection were identified in the Danish Pancreatic Cancer Database (DPCD). Thirty patients died within 10 weeks postoperatively; 78 received other regimens or preoperative chemotherapy and were excluded. Of the remaining 623 patients, the chemotherapy (CT) group (n = 409, 66%) received gemcitabine within 10 weeks after resection, whereas the non-chemotherapy (NCT) group (n = 214, 34%) did not receive CT within 10 weeks. Results: CT patients were slightly younger than NCT patients but did not otherwise differ in baseline characteristics. The CT group showed a mOS of 24 months (95% CI; 21–27) and a 5-year survival rate of 22% (95% CI; 17–27); the NCT group had a mOS of 22 months (95% CI; 16–26, p = .27) and a 5-year survival rate of 26% (95% CI; 19–34, p = .66). Most patients (415/623) had lymph node metastases. Of these patients, those in the CT group (n = 280) had significantly longer mOS [20 months (95% CI; 18–24)] than those in the NCT group (n = 135) [14 months (95% CI; 11–17)]. Conclusions: In this national Danish cohort of PC patients undergoing resection between 2011 and 2016, the survival after postoperative gemcitabine was similar to that reported in previous clinical trials. However, the survival advantage of postoperative gemcitabine was limited to patients with lymph node metastases.

Published
2019
Full Text
View/download PDF

46. Interindividual changes in peak oxygen consumption in patients with colorectal cancer following endurance training:a secondary analysis of the I-WALK-CRC study

Author

Thomsen, Simon Nørskov, Sundberg, Anna, Osterkamp, Jens, Thorsen-Streit, Sarah, Østerlind, Kell, Krarup, Peter Martin, Vistisen, Kirsten, Pedersen, Bente Klarlund, Christensen, Jesper Frank, Thomsen, Simon Nørskov, Sundberg, Anna, Osterkamp, Jens, Thorsen-Streit, Sarah, Østerlind, Kell, Krarup, Peter Martin, Vistisen, Kirsten, Pedersen, Bente Klarlund, and Christensen, Jesper Frank

Published
2020

48. Supplement II: Abstracts of the international symposium on Skin Carcinogenesis in man and in experimental models. Heidelberg, 29–31 October 1991 (pp S61–S88)

Author

Barrett, J. C., Afshari, C. A., Annab, L. A., Burkhart, B. A., Boyd, J. A., Owen, R. D., Futreal, P. A., Richter, K. H., Moses, H. L., Lavker, R. M., Miller, Stanley, Sun, T. -T., Stingl, G., Bianchi, A. B., Navone, N. M., Conti, C. J., Spencer, James M., Kahn, S., Weinstein, I. B., Silvers, D. S., DeLeo, V. A., Larcher, F., Bauluz, C., Quintanilla, M., Ballestin, C., Jorcano, J. L., Schön, M., Haas, M., Klein, C. E., Weber, L., Cerri, A., Tadini, G., Gitto, R., Berti, E., Cano, A., Caulín, C., Gómez, M., Gandarillas, A., Martín, M., Montes, A., Navarro, P., Bastian, B. C., Van der Piepen, U., Römisch, J., Pâques, E., Hartmann, A. A., Krieg, P., Schnapke, R., Feil, S., Fürstenberger, G., Marks, F., Missero, C., Cajal, S. Ramon y, Filvaroff, E., Dotto, G. P., Sherman, J., Albert, R. E., Baxter, C. S., Bauer, G., Höfler, P., Götschl, M., Viesel, E., Jürgensmeier, J., Schaefer, D., Picht, G., Grande, T., Real, A., Rünqer, T. M., Möller, K., Fuchs, P., Bauer, C., Epe' B., Gruner, S., Diezel, W., Macejewski, J., Weber, H., Eckert, R., Volk, H. D., Sönnichsen, N., Bavinck, Jan N. Bouwes, Vermeer, Bert J., Van Der Woude, Fokko J., Vandenbroucke, Jan P., Claas, Frans H. J., Griffin, E. F., Harris, H., Tilgen, W., Garbe, C., Østerlind, Anne, Weiss, J., Jung, E. G., Ruiter, D. J., Danen, E., Broecker, E. -B., Johnson, J. P., van Muijen, G. N. P., Halaban, R., Krüger-Krasagakes, S., Orfanos, C. E., Newton, J. A., Bataille, V., Cuzick, J., Bishop, T., Schwaaf, A., Azizi, E., Bröcker, E. B., Eberlein, B., Froschermaier, S., Gollhausen, R., Przybilla, B., Krasagakis, K., Abdel-Naser, M. B., Lopez-Bran, E., Robledo, A., Lopez-Bran, E., Heine, H., Hennig, B., Graf, G., Nährig, J., Niedner, R., Schöpf, E., Mailhammer, R., Reisbach, G., Kempkes, B., Hültner, L., Thalmeier, K., Anders, F., Zechel, C., Schleenbecker, U., Leers, J., Smith, A., Wagner, E., Burcin, U., Hug, H., Fiebich, B., Anders, A., Gröger, H., Schlatterer, B., Moll, I., Wollina, U., Leigh IM, Purkis PE, Markey A., Neill S., Proby C., Glover M., Lane EB, Klein-Szanto, A. J. P., Yaar, M., Garmyn, M., Gilani, A., Gilchrest, B. A., Bowden, G. T., Nelson, M., Levy, J., Tanooka, Hiroshi, Ootsuyama, Akira, Urbach, F., van der Leun, J. C., de Gruijl, F. R., Kripke, Margaret L., Yuspa, S. H., Glick, A., Lee, E., Diugosz, A., Balmain, A., Bums, P., Kemp, C. J., Stoler, A. B., Harks, F., Boukamp, P., Pascheberg, U., Breitkreutz, D., Hülsen, A., Altmeier, S., Tomakidi, P., Fusenig, N. E., Lowy, Douglas R., Sedman, Sylvia A., Cohen, Bruce D., Schiller, John T., Kricker, A., Armstrong, B. K., English, D., Heenan, P. J., Randell, P. L., de Gruijl, F. R., Kelfkens, G., van Weelden, H., van der Leun, J. C., Grabbe, S., Bruvers, S., Granstein, R. D., Albert, R., Miller, M., Cody, T., Baxter, C., Shukla, R., Ueda, M., Ichihashi, M., Yamamura, K., Hayashibe, K., Funasaka, Y., Mishima, Y., Fujiwara, Y., Ichihashi, M., Jimbo, T., Mishima, Y., Popanda, O., Thielmann, H. W., Jahrens, D., Edler, L., Ootsuyama, A., Tanooka, H., Sutter, C., Mukhtar, H., Strickland, P. T., Winter, H., Schweizer, J., Schmidt, R., Weber, E., Rippmann, F., Hecker, E., Kopp-Schneider, A., Lehmann, W. D., Stephan, M., Troll, W., Wei, H., Fujiki, H., Garte, S. J., Frenkel, K., Svetek, J., Schara, M., Pečar, S., Hergenhahn, M., Kinzel, V., Richards, J., Plein, P., Schiess, K., Kaszkin, M., Yamamoto, S., Wang, J. C., Kato, R., Kuroki, T., Hashimoto, Y., Osada, S., Ohno, S., Gilles, C., Piette, M., Foidart, J. -M., Ranki, A., Lassus, J., Lehmus, A., Niemi, K. -M., Friesel, H., Schneider, T., Steinbauer, B., Sorg, B., Winter, A., Krauter, G., Krauß, R., Roeser, H., Unger, Sylvia, Janiaud, Paul, Rueß, Doris, Mechler, Bernard M., Stanbridge, Eric J., Gross, Monika M., Buček, M., Klein-Bauernschmitt, P., Schlehofer, J. R., Kosters, R., Stark, H. -J., Okulov, V. B., Elgjo, K., Ushmorov, A. G., Danilov, A. O., Zubova, S. G., Furstenberger, G., and Faissner, A.

Published
1991
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results